Could stem cells save failing kidneys? mayo clinic launches new trial
NCT ID NCT06752577
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether stem cells from donated bone marrow are safe for people with chronic kidney disease, including those who have had a kidney transplant. Up to 75 participants will receive the cells through an IV or directly into the kidney arteries, with repeat doses allowed every 6 months. The main goal is to check for side effects, not yet to prove the treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Mayo Clinic
RECRUITINGJacksonville, Florida, 32224, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bone marrow-derived mesenchymal stem cells (MSCs)
What this could lead to
If successful, this could point toward a new way to slow or manage chronic kidney disease, potentially reducing the need for dialysis or repeat transplants.
What could go wrong
This is an early safety trial with only 75 participants, so it is too soon to know if the stem cells actually help. There are also risks from the infusion procedure, including possible allergic reactions or kidney damage.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.